Consumer willingness to pay for weight-loss drugs surprises Novo CEO
People have been very willing to pay for Novo Nordisk’s obesity drugs themselves, the CEO states.
by ritzau
Novo Nordisk CEO Lars Fruergaard Jørgensen is surprised that European consumers have been so willing to pay for weight loss drugs themselves, he says in an interview with the British business media Financial Times.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
